MedTrace Logo

PK Study of Anti-TB Drugs

NCT02457208 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2018-10-03

No results posted yet for this study

Summary

This is a prospective descriptive and pharmacokinetic study will be conducted among newly diagnosed patients registered in the two SMRU TB clinics located on the Thai-Myanmar border. This study aims to recruit (1) 30 adults with HIV co-infection and (2) 30 adults without HIV co-infection in one year. Patients will be given the standard 6 month anti-TB drugs as per WHO guidelines.

Conditions

Interventions

DRUG

Isoniazid (H)

DRUG

Rifampicin (R)

DRUG

Pyrazinamide (Z)

DRUG

Ethambutol (E)

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-07
Primary Completion
2018-01-14
Completion
2018-01-14

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02457208 on ClinicalTrials.gov